Drug Trial Radar · NCT06416358
A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed
Last checked: Nov 20, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
May 2024
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- AlaMab Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bone metastasis is a common disease of advanced tumors. It refers to the metastasis of malignant tumors originating in a certain organ to the bones through the blood circulation or lymphatic system. The incidence of bone metastasis in breast and prostate cancer is as high as 65%-75%. Bone metastasis of malignant tumors often leads to severe bone lesions, including bone pain, pathological fractures, spinal cord compression, hypercalcemia and other bone-related events (SRE). SRE caused by bone metastasis of tumors can greatly reduce the quality of life of tumor patients. In severe cases, it can lead to rapid deterioration of the condition or even death, which greatly affects the extension of the patient's survival period. ALMB-0168 is designed to activate Cx43 hemichannels, which release key anti-cancer factors (such as ATP) into the extracellular environment. In several mouse models of breast cancer bone metastasis and orthotopic osteosarcoma, ALMB-0168 dose-dependently inhibited tumor growth and was able to extend the lifespan of tumor-bearing animals, indicating its potential as a therapeutic drug for malignant bone tumors. . Clinical research data from China and Australia show that ALMB-0168 is safe and initially effective in patients with bone metastasis and osteosarcoma;
Conditions
- Advanced Solid Tumors With Bone Only Metastasis
Interventions
ALMB-0168Drug
ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The 6-month progression-free survival rate (6m-PFSR) of cohort A breast cancer IRC assessed according to RECIST 1.1 criteriaTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 3 years
- The 4-month progression-free survival rate (6m-PFSR) assessed by cohort B prostate cancer Independent Review Committee(IRC) based on PCWG 3 criteria Progression-free survival rate (4m-PFSR);Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 3 years
- RP2DTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.